奥沙利铂联合替吉奥与FOLFOX4治疗晚期胃癌的比较  

Comparison of S-1 combined with oxaliplatine and FOLFOX4 in the treatment of patients with advanced gastric cancer

作　　者：姜孝娟[1] 胡冰[1] 季楚舒[1] 何义富[1] 王勇[1] 

机构地区：[1]安徽医科大学附属省立医院肿瘤科,安徽合肥230001

出　　处：《安徽医药》2012年第7期1000-1002,共3页Anhui Medical and Pharmaceutical Journal

摘　　要：目的观察奥沙利铂联合替吉奥方案与FOLFOX4方案治疗晚期胃癌的近期疗效和毒副反应。方法 42例晚期胃癌的患者随机分为奥沙利铂联合替吉奥组和FOLFOX4方案组,两组均化疗2个周期,按RECIST标准进行评价并比较两组近期疗效及毒副反应。结果奥沙利铂联合替吉奥组CR 2例,PR 9例,有效率52.4%,FOLFOX4组CR 1例,PR 9例,有效率47.6%,两组有效率无显著性差异(P>0.05)。两组主要不良反应为血液学毒性,胃肠道反应和神经系统毒性。其中FOLFOX4组恶心,呕吐发生率显著高于替吉奥联合奥沙利铂组,两组数据比较在统计学上有显著性差异(P<0.05)。结论奥沙利铂联合替吉奥方案与FOLFOX4方案治疗晚期胃癌疗效相似,但耐受性稍好。Objective To evaluate the efficacy and toxicity of S-1 combined with oxaliplatine and FOLFOX4 therapy in the treatment of patients with advanced gastric cancer. Methods Fourty two patients with advanced gastric cancer were enrolled into this study. They were randomly divided into S-1 combined with oxaliplatine therapy group and FOLFOX4 therapy group respectively. All patients received two cycles of chemotherapy at least. The efficacy and toxicity were evaluated according to RECIST standard. Results The overall effective rate in S-1 combined with oxaliplatine therapy group was 52.4%, and in FOLFOX4 therapy group was 47.6% （ P 〉 0.05 ）. The major toxicities included myelosuppression, gastrointestinal reaction and peripheral nerve toxicitity. The incidence of nausea and vomiting in FOLFOX4 group was higher than that in S-I combined with oxaliplatine. Conclusion The response of S-1 combined with oxaliplatine regimen for advanced gastric cancer is similar, and the toxicity of S-1 combined with oxaliplatine is tolerable.

关 键 词：胃癌 替吉奥 奥沙利铂 联合化疗 

分 类 号：R735.2[医药卫生—肿瘤]